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The advent of percutaneous transluminal angioplasty
(PTA)/stenting has prompted many investigators to advo-
cate this as the procedure of choice for carotid restenosis
because it is perceived that reoperation carries higher peri-
operative stroke rates and cranial nerve injury rates than
primary CEA.9-13
This present study compares the early and late out-
comes of reoperation and PTA/stenting for carotid
restenosis. Only one previous study compares the opera-
tive and endovascular treatment of carotid restenosis from
the same institution.13
PATIENT POPULATION AND METHODS
All reoperations (Group I, 58 patients) and PTA/
stenting (Group II, 25 arteries in 23 patients) for carotid
restenosis that were performed during a recent 4-year
period between June 1996 and June 2000 by one vascular
surgeon (AFA) and one vascular medicine interventionalist
(MB) at the same institution were analyzed. Patients who
had PTA/stenting were considered by their surgeons to be
too high-risk for conventional reoperation. These include 2
patients with previous neck irradiation, 5 with high cervi-
cal lesions (based on previous CEA findings), and 3 with
past cranial nerve injuries (two vagal nerves and one
hypoglossal nerve). In 13 other patients, the surgeons
Carotid endarterectomy (CEA) is considered the surgi-
cal intervention of choice for symptomatic and asymptom-
atic carotid artery stenosis. This procedure has been
performed with increasing frequency since the conclusion of
the North American Symptomatic Carotid Endarterectomy
trial and the Asymptomatic Carotid Atherosclerosis Study
trial.1,2 Reoperation for restenosis is much more controver-
sial because of the more benign nature of these lesions, espe-
cially those occurring within 2 years of the CEA.3-7
Reoperation for significant carotid restenosis is gener-
ally indicated for patients with symptomatic disease.3-7
Other authors also recommend reoperation for >80%
asymptomatic restenosis.8
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Purpose: This study is a nonrandomized parallel comparison of the outcome for carotid endarterectomy (CEA) and per-
cutaneous transluminal angioplasty (PTA)/stenting for recurrent carotid artery stenosis (RCS).
Methods and Patients: Between June 1996 and June 2000, 83 carotid procedures (58 reoperations, Group I, and 25
PTA/stentings, Group II) were done for RCS. Patients were followed at regular intervals with duplex ultrasound scan-
ning. The outcome of the stented group (Group II) was divided into early experience (Group IIA, first 12 cases) and
late experience (Group IIB, last 13 cases) for learning curve consideration, and each was compared with the reopera-
tion group. A Kaplan-Meier life table analysis was used to estimate the stroke-free survival rates and freedom from
≥50% recurrent restenosis for both groups.
Results: The demographic and clinical characteristics and indications for intervention were similar for both groups. The
mean time from the original CEA to reoperation was 41 months in Group I versus 43 months in Group II. Overall,
stenting had higher 30-day stroke rates than reoperations—16% (3 major and 1 minor stroke) versus 3.4% (1 out of 2
[1.7%] was a major stroke, P < .05). However, Group IIB had similar major stroke rates to Group I (0% versus 1.7%).
Cranial nerve injury was noted in 10 patients (17%) in Group I (only 1 [1.7%] was permanent) versus 0% in Group II
(P < .05). Recurrent ≥50% restenosis was higher in Group II than in Group I (24% versus 0%, P < .001). Stroke-free
survival rates at 6 months and 1, 2, and 3 years for Group I were 97%, 97%, 94%, and 82%, respectively, versus 79%,
79%, 79%, and 79%, respectively, for Group II (P = .059). Freedom from recurrent ≥50% restenosis rates at 6 months
and 1, 2, and 3 years were 100%, 100%, 100%, and 100%, respectively, for Group I versus 100%, 94%, 65%, and 44%,
respectively, for Group II (P < .0001).
Conclusions: Carotid PTA/stenting has a similar 30-day stroke rate to that of reoperation for RCS once experience is
established. However, PTA/stenting has a higher incidence of restenosis than reoperation, which is associated with a
percentage of cranial nerve injuries. Therefore, PTA/stenting can be an alternative to reoperation, particularly in mar-
ginal surgical risk patients. (J Vasc Surg 2001;34:831-8.)
(general and cardiac surgeons with vascular privileges) felt
that they were too morbid for reoperation. All patients
underwent carotid color duplex ultrasound scan/magnetic
resonance angiography and arteriography before reopera-
tion. Preoperative risk factors were determined for each
patient, along with the preoperative use of antiplatelet
therapy. Indications for surgery were categorized into
hemispheric transient ischemic attacks (TIAs), hemispheric
strokes, amaurosis fugax, nonhemispheric TIAs, and
asymptomatic carotid restenoses. All patients with reopera-
tions were administered aspirin therapy (325 mg daily) if
not contraindicated, within 24 hours after the operation.
Patients who underwent PTA/stenting were administered
aspirin therapy and ticlopidine (Ticlid, 250 mg twice daily)
or clopidogrel bisulfate (Plavix, 300 mg, followed by 75
mg daily) for 30 days. Aspirin therapy was continued indef-
initely as it was in patients with reoperations.
All reoperations were performed under general anesthe-
sia with systemic heparin and routine shunting using a carotid
Argyle shunt (C. R. Bard, Inc, Billerica, Mass). Polytetra-
fluoroethylene (Goretex) patch angioplasties alone were
done on 36 arteries (early lesions, ≤24 months), and 22 other
arteries (late lesions, ≥24 months) underwent re-endarterec-
tomy with patch angioplasty in 20 cases, and two other
lesions (25 and 26 months) had PTFE patch angioplasty
alone. None of these patients had interpositional grafts.
The following were contraindications for reoperations
or PTA/stenting: intracranial stenosis that exceeded the
severity of the extracranial stenosis, severe disability from
stroke, presence of severe aortoiliac or peripheral vascular
disease that precluded vascular access for PTA/stenting,
and inability to give informed consent.
Carotid PTA and stenting protocol. Aspirin (325
mg daily) and ticlopodine (Ticlid, 250 mg twice daily) or
clopidogrel bisulfate (Plavix, 75 mg daily) were given for
7 days before the procedure and on the morning of the
procedure. Preoperative sedation was avoided. Using local
anesthesia with 1% xylocaine, the surgeon introduced a 5-
French sheath into the common femoral artery by using
the modified Seldinger technique. Through this sheath, a
5-French diagnostic catheter was used to selectively
engage the innominate or carotid arteries for angiography
after an oblique arch aortogram was performed. The
catheter was navigated into the common carotid artery,
allowing selective angiography of the vessel to be per-
formed in orthogonal views, and 5000 units of heparin
were administered intravenously. In the first six cases,
10,000 units of intravenous heparin were given, but
because of one case of intracerebral hemorrhage during
this time, the dosage was decreased to 5000 units. A
guidewire was navigated into the external carotid artery,
and the diagnostic catheter was advanced into the distal
external carotid artery. A 0.038-inch exchange length sup-
port wire was placed in the external carotid artery, and the
catheter was removed. A 9-French multipurpose catheter
with a 7-French introducer was then inserted over the sup-
port wire and advanced into the area of interest using
meticulous fluoroscopic guidance. The introducer and
support wire were removed, and the catheter was flushed
using the retrograde flush technique. The target lesion
was crossed with a soft-tipped 0.018-inch wire and dilated
with a 4-mm balloon catheter. Finally, the stent was
deployed in the internal carotid artery, which may extend
into the common carotid artery, if needed. This was fol-
lowed by post-stent balloon angioplasty in our early expe-
rience; however, postdilatation was avoided when possible
during the last 2 years. The length and size of the stent
were determined according to angiography. A completion
angiogram, including digital subtraction intracranial
angiography, was performed.
Post-stent anticoagulation was not used; however, all
patients were continued on ticlopodine (Ticlid, 250 mg
twice daily) or clopidogrel bisulfate (Plavix, 300 mg initial
dose, followed by 75 mg daily) for 30 days, and aspirin
was continued indefinitely.
Femoral venous access was gained in some patients,
and a pacemaker was either placed on the right ventricle or
made available for the treatment of a rare malignant brady-
cardia or asystole during the balloon inflation procedure.
All patients underwent placement of a single stent,
except for one patient who had two stents. The type of
stents used included Palmaz stent (J & J Interventional
Systems, Warren, NJ) in the first two patients and Wall stent
(Boston Scientific, Natick, Mass) or Smart stent (Cordis
Endovascular, Warren, NJ) in the remaining patients.
Surveillance protocol. All patients underwent clini-
cal follow-up, and every effort was made for these patients
to have immediate postoperative color duplex ultrasound
scanning, to be repeated at 30 days, 6 months, 12 months,
and every year thereafter, with an ATL Ultramark 9 HDI
system or HDI 3000 system (Advanced Technology
Laboratory, Inc, Belleview, Wash). Duplex scanning was
used to detect the presence of recurrent restenosis after
reoperation or carotid PTA/stenting.
Angiographic success after carotid PTA/stenting was
defined as achieving <30% residual stenosis. Neurologic
complications were classified as one of the following: a
TIA, which was defined as a new neurologic deficit that
resolved completely within 24 hours; a minor stroke, a new
neurologic deficit that either resolved completely within 7
days or increased the National Institutes of Health stroke
scale score by three or less; or a major stroke, a new neu-
rologic deficit that persisted after 7 days and increased the
National Institutes of Health stroke scale score by four or
more. If a patient had a neurologic deficit after PTA/stent-
ing or reoperation, magnetic resonance imaging or com-
puted tomography of the head was performed.
STATISTICAL METHODS
The time to the occurrence of events (time to ≥50%
recurrent restenosis, time to stroke or death) was calcu-
lated using the Kaplan-Meier method. Statistical compar-
isons were made with the Wilcoxon rank sum test. The
statistical comparison of continuous data were examined
with the unpaired Student t test, and discrete variables
were compared with the χ2 or Fisher exact test.
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The outcome of the stented group (Group II) was
divided into early experience (Group IIA, the first 12
cases) and late experience (Group IIB, the last 13 cases)
for learning curve consideration, and each group was com-
pared with the reoperation group. This cutoff of 12 cases
was based on the recommendation of the Carotid
Revascularization: Endarterectomy versus Stenting Trial
group that the interventionalist select 12 to 15 run-in
cases of PTA/stenting before formal randomization, and
it happened that the last stroke in our PTA/stenting
group was the twelfth case.
RESULTS
The demographic and clinical characteristics were sim-
ilar in both groups (Table I). There were 25 PTA/stents
in 23 patients, two of whom had the same side stented
twice. One of these patients had a Palmaz stent initially for
an asymptomatic lesion, followed by restenting using a
Smart stent for ≥80% asymptomatic restenosis in 24
months. The other patient had a Smart stent initially for
TIA symptoms, followed by restenting with another Smart
stent for ≥80% asymptomatic restenosis in 12 months. The
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indications for intervention were as follows: 46 (79%) ver-
sus 18 (72%) for symptomatic restenoses and 12 (21%)
versus 7 (28%) for high-grade (>80%) asymptomatic
restenoses for Groups I and II, respectively. The mean
time from the original CEA to reoperation was 41 months
in Group I versus 43 months in Group II. The initial suc-
cess rate for PTA/stenting was 100%. Palmaz stents were
used in our early experience in two patients, Wall stents in
13 patients, and Smart stents in 10 patients.
Table II summarizes the 30-day and all neurologic com-
plications for both groups. Overall, PTA/stenting had
higher ipsilateral stroke rates (20%) than reoperations (3.4%,
P < .05). There were four (16%) 30-day strokes in Group II
patients, three of which were major strokes and one of which
was a minor stroke, in contrast with two (3.4%, one major
and one minor) in Group I (P = .064). Three out of four
lesions in Group II patients who had early strokes were late
recurrent lesions (>24 months after original primary CEA)
versus one out of two lesions in Group I. The 30-day stroke
rates were comparable between reoperation and PTA/stent-
ing, whether the indication for intervention was symptom-
atic or asymptomatic (three out of four patients with
Table I. Demographic/clinical indications—reoperation versus PTA/stenting
Reoperation PTA/stenting P value
No. of arteries (patients) 58 (58) 25 (23)
Mean age (y) (range) 70 (48-81) 71 (46-82) NS
Female sex 32 (53%) 12 (52%) NS
Smoking 35 (60%) 15 (65%) NS
Diabetes mellitus 13 (22%) 6 (29%) NS
Hypertension 45 (78%) 19 (76%) NS
Hypercholesterolemia 33 (57%) 14 (61%) NS
Coronary artery disease 31 (53%) 13 (57%) NS
Indications for procedure
Symptomatic, TIA/stroke 46 (79%) 18 (72%) NS
Asymptomatic 12 (21%) 7 (28%) NS
Mean time from original CEA to reoperation (mo) (range) 41 (4-249) 43 (6-238) NS
Mean time to follow up (mo) (SE) 22.1 (1.61) 18.1 (3.01) NS
NS, Not significant.
Table II. 30-day perioperative and all neurologic complications
Complication Reoperation CEA PTA/stenting P value
Number of arteries (patients) 58 (58) 25 (23)
All ipsilateral strokes 2 (3.4%) 5 (20%) .024
Major stroke 1 (1.7%) 4 (16%) .027
Minor stroke 1 (1.7%) 1 (4%) NS
Perioperative ipsilateral strokes
Major and minor 2 (3.4%) 4 (16%) .064
Major 1 (1.7%) 3 (12%) .079
Ipsilateral TIA 1 (1.7%) 1 (4%) NS
Death 0 ( 1 (4%) NS
Bleeding 1 (1.7%) 1 (4%) NS
Cranial nerve injury, total 10 (17.2%) 0 ( .028
Transient 9 (15.5%) 0 ( .05
Permanent 1 (1.7%) 0 ( NS
NS, Not significant.
perioperative strokes in the PTA/stenting group were symp-
tomatic versus two out of two in patients with reoperations).
The causes of 30-day strokes in Group II patients were
embolic in three (two major and one minor stroke) and
intracerebral hemorrhage in one. All of these patients had a
normal perioperative completion angiogram. All three
embolic strokes had poststenting dilatation. One of the
patients with cerebral hemorrhage was complicated by mul-
tiple organ failure and died perioperatively (this patient had
string sign). A fifth patient in Group II (for a late lesion) had
an embolic stroke at 32 days postoperatively, which was
attributed to ventricular thrombus. The cause of the 30-day
strokes in the two patients with reoperations was also
embolic with a normal duplex ultrasound scan. There was
one major bleeding (noncerebral) in a patient with
PTA/stenting. This patient was approached by femoral
puncture of the left limb of the aortobifemoral graft that was
complicated by postoperative bleeding, necessitating explo-
ration and repair of a tear in the femoral graft; however,
immediate postoperative thrombosis developed in this
patient and below-knee amputation was eventually required.
Table III summarizes the 30-day and all neurologic
complications in Groups IIA and IIB patients. As noted,
the four 30-day strokes in Group II occurred in the first
12 cases, and none occurred in the last 13 cases of
PTA/stenting (P = .04).
Table IV compares the results of the reoperations
(Group I) to the last 13 carotid stenting cases (Group
IIB). As noted, there were no significant differences in the
30-day stroke or TIA rates or other 30-day complications.
The ≥50% recurrent restenosis rate was higher in
Group II than in Group I (6 [24%] versus 0, P < .001).
The stroke-free survival rates at 6 months and 1, 2,
and 3 years for Group I were 97%, 97%, 94%, and 82%,
respectively, versus 79%, 79%, 79%, and 79%, respectively,
for Group II (P = .059) (Table V, Fig 1). The freedom
from recurrent ≥50% restenosis at 6 months and 1, 2, and
3 years were 100%, 100%, 100%, and 100%, respectively,
for Group I versus 100%, 94%, 65%, and 44%, respectively,
for Group II (P < .0001) (Table VI, Fig 2). The stroke-
free survival rates and freedom from recurrent ≥50%
restenosis rates at 1 year for Groups I and IIB patients
were similar (97% and 100% versus 100% and 80%, respec-
tively).
DISCUSSION
Restenosis of the carotid artery has been detected with
increasing frequency because of the increased use of non-
invasive testing. Even though the incidence of restenosis
has been reported to range from 1% to 36%,14,15 only 1%
to 8% of all patients undergoing CEA will develop hemo-
dynamically significant restenosis. Early restenoses are
JOURNAL OF VASCULAR SURGERY
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Table III. 30-day perioperative and all neurologic complications: First 12 cases (Group IIA) versus last 13 cases
(Group IIB) of PTA/stenting
Complication Group IIA (n = 12) (%) Group IIB (n = 13) (%) P value
All ipsilateral strokes 5 (41.7) 0 .01
30-day ipsilateral strokes 4 (33.3) 0 .04
Ipsilateral TIA 1 (8.3) 0 NS
Death 1 (8.3) 0 NS
Bleeding* 0 1 (7.7) NS
*This patient complicated with leg amputation (see “Results” section).
NS, Not significant.
Table IV. Perioperative complications with reoperation (Group I) versus last 13 carotid PTA/stenting cases (Group
IIB)
Complication Reoperation (n = 58) (%) PTA/stenting, (n = 13) (%) P value
Ipsilateral stroke 2 (3.4) 0 NS
Major stroke 1 (1.7) 0 NS
Minor stroke 1 (1.7) 0 NS
Ipsilateral TIA 1 (1.7) 0 NS
Death 0 0 NS
Bleeding 1 (1.7) 1 (7.7) NS
Cranial nerve injury, total 10 (17.2) 0 NS
Transient 9 (15.5)* 0 NS
Permanent 1 (1.7)† 0 NS
*These include 4 hypoglossal nerves, 3 vagal/brachial nerves (1 superior laryngeal nerve, 1 recurrent laryngeal nerve, and 1 main vagal nerve), and 2 mar-
ginal mandibular branches of the facial nerve.
†This was one recurrent laryngeal nerve.
NS, Not significant.
mostly a consequence of myointimal hyperplasia, and
those occurring after 2 years are generally associated with
atherosclerosis.7,16,17
There is a general consensus among surgeons that reop-
eration for significant symptomatic restenosis is indicated,
whereas the indication for reoperation for asymptomatic
restenosis is somewhat controversial.4,5,8 Reoperation is
generally believed to be more difficult than primary CEA,
largely because of the dense scarring surrounding the
carotid artery and the difficulty in obtaining tissue cleavage
planes. Higher morbidity and mortality rates (8%-20%) after
reoperation have been documented,6,7,9,18 although some
recent studies suggest that the risk has improved.15,19-21
O’Donnell et al8 also reported on the results from a meta-
analysis of six series that showed a 4.2% stroke rate and a 1%
mortality rate, for a combined rate of 5.2%. He also indi-
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cated that the incidence of cranial nerve injuries in patients
with reoperation surgery averaged 8.5% in these series ver-
sus 16% in his series.8
Recently, Hill et al21 reported lower 30-day stroke and
death rates for reoperation (0%) compared with primary
CEA (1.1%) in a group of 390 CEAs (40 reoperations and
350 primary CEAs).
Carotid PTA/stenting is increasing in popularity and
has been advocated by some investigators as an alternative to
reoperation for carotid restenosis.9-13 The safety and efficacy
of this approach is currently being investigated. The Carotid
Revascularization: Endarterectomy versus Stenting Trial,22
which is currently underway, is comparing the results of
operative and PTA/stenting for primary carotid stenosis.
Angioplasty/stenting has been justified for the treat-
ment of restenosis on the basis that this procedure is sim-
Table V. Life table analysis of time to stroke or death for reoperation (Group I) and carotid PTA/stenting (Group II)
patients
Interval (mo) No. at risk at start No. failed Stroke-free survival rate (%) Standard error (%)
Group I
Entry 58 0 100 0
1 56 2 98 1.7
6 50 2 97 2.4
12 45 0 97 2.4
24 27 1 94 3.6
36 12 2 82 8.4
42 4 1 73 11.4
Group II
Entry 25 0 100 0
1 21 4 87 3.9
6 14 5 79 8.5
12 11 0 79 8.5
24 4 0 79 8.5
36 1 0 79 8.5
42 1 0 79 8.5
Table VI. Life table analysis of time to recurrent ≥50% restenosis for reoperation (Group I) and carotid PTA/stenting
(Group II) patients
Interval (mo) No. at risk at start ≥50% restenosis Recurrent stenosis–free rates (%) Standard error (%)
Group I
Entry 58 0 100 0
1 58 0 100 0
6 52 0 100 0
12 46 0 100 0
24 28 0 100 0
36 11 0 100 0
42 3 0 100 0
Group II
Entry 25 0 100 0
1 24 0 100 0
6 19 0 100 0
12 15 2 94 5.7
24 6 3 65 12.9
36 2 1 44 19.7
42 1 0 44 19.7
ple to perform and the pathology of early restenosis is
myointimal hyperplasia, rendering these patients amenable
to PTA. It is generally believed that such hyperplastic
lesions are not likely to embolize.
Yadav et al11 reported on their experience with 25
CEAs (22 patients) treated with PTA and stenting for
carotid restenosis and found a 4% perioperative stroke rate
with no secondary restenoses at 6-month follow-up.
Lanzino et al23 reported on their experience with 25
PTA/stentings on 21 patients for carotid restenosis with
no major periprocedural neurologic deficits or deaths.
There was one periprocedural TIA, and a pseudoaneurysm
of the femoral artery developed in another patient at the
access site, which required surgical repair. In 16 patients
who underwent at least 6 months of follow-up review, no
neurologic events ipsilateral to the treated artery had
occurred after a mean follow-up period of 27 months.
Significant restenosis (≥50%) was observed in only one of
the vessels treated. The authors concluded that
PTA/stenting for carotid restenosis is both technically fea-
sible and safe and has a satisfactory midterm patency and
should be considered a valuable alternative to reoperation
in patients with carotid restenosis.
Bergeron et al10 reported on the results of PTA/stenting
for carotid restenosis in 15 patients (11 had PTA alone and 4
had stenting). Two postdilatation complications (dissection
and acute occlusion) required prompt stenting; one common
carotid artery was stented for postdilatation residual stenosis,
and one recurrent lesion was stented 6 months after the ini-
tial angioplasty. They also reported 1 stroke, 1 silent cerebral
infarction, and 3 TIAs (33% neurologic complication rate),
and one patient died 3 days postoperatively from hyperper-
fusion syndrome. Long-term follow-up in two stent patients
showed no restenosis at 18 and 48 months. The 11 PTA
patients, likewise, have not demonstrated restenosis. They
concluded that PTA alone appeared to be too risky for treat-
ing restenosis. However, stents may offer a safer alternative,
particularly when implanted primarily.
In a recent multicenter study, New et al24 reported on
the safety, efficacy, and durability of carotid stenting for
restenosis after CEA. Three hundred fifty-eight arteries
(338 patients) had carotid PTA/stenting. The average
duration from the CEA to carotid stenting was 5.5 years.
Sixty-one percent of these patients were asymptomatic.
The 30-day stroke and death rate was 3.7%. The minor
stroke rate was 1.7%, the major nonfatal stroke rate was
0.8%, and the fatal stroke rate was 0.3%. There was one
(0.3%) fatal and one (0.3%) nonfatal stroke during the fol-
low-up period. Overall, the 3-year rate of freedom from all
fatal and nonfatal strokes was 96% ± 1% (± SE). They con-
cluded that carotid artery stenting can be performed in
patients with restenosis with 30-day perioperative compli-
cation rates, comparable with most published series on
reoperation. They also indicated that the technique was
durable and efficacious.
None of these reports compared reoperation to
PTA/stenting for carotid restenosis in the same institu-
tion. To our knowledge, there has only been one compar-
ative study between reoperation and carotid PTA/stenting
for carotid restenosis.13
Hobson et al13 reported comparable early results for
reoperation and PTA/stenting for patients with carotid
restenosis. During an 8-year period, early restenosis (18
months after primary CEA) was managed with reopera-
tion in 16 cases and with carotid PTA/stenting in 15 oth-
ers. There were no 30-day strokes or deaths in either
group. Duplex ultrasound scan results in the PTA/stent-
ing group revealed no restenosis or stent occlusion with a
mean follow-up of 7 months.
A direct comparison of CEA versus stenting is difficult
in this retrospective study because many patients who
underwent carotid stenting were considered nonsurgical
candidates because of the high cervical location of the
lesion, previous cranial nerve injury, or severe comorbidi-
ties. However, we attempted to create as much uniformity
as possible in our two study groups to draw an accurate
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Fig 1. Kaplan-Meier curves for stroke-free survival rates for
Groups I and II.
Fig 2. Kaplan-Meier curves for freedom from recurrent ≥50%
restenosis rates for Groups I and II.
comparison. Both groups had similar clinical and demo-
graphic characteristics, and only one surgeon’s and one
vascular medicine interventionalist’s experiences were ana-
lyzed. Overall, stenting had higher stroke rates than reop-
eration when all patients with stenting were included (20%
versus 3.4%, P < .05). However, when the outcome of the
stented group was subdivided into early and late experi-
ence for learning curve consideration, the stenting group
had a major stroke rate similar to the reoperation group
(0% versus 1.7%). It should be noted that the number of
arteries in Group IIA and IIB were 12 and 13, respec-
tively, which carries with it a substantial chance of a type
II statistical error because of the small sample size. The
early high stroke rates with carotid stenting were most
likely related to patient selection and learning curve.
Changes in anticoagulation, avoiding subtotal “string
sign” lesions with baseline slow flow, and poststent dilata-
tion practice changes have positively influenced the out-
come in Group IIB. Al-Mubarak et al25 reported that
patients who were more than 80 years old or who had tor-
tuosity of the aortic arch or carotid artery have a greater
likelihood of embolic event during carotid PTA/stenting.
None of our PTA/stenting patients had this pathology,
and only one patient was more than 80 years old. As
expected, we found an increase in the number of transient
cranial nerve injuries (17%) in the reoperation group;
however, only 1.7% had a permanent cranial nerve injury.
As noted in Table V, the stroke-free survival rate at 6
months and 1, 2, and 3 years for reoperation were some-
what better than for Group II (stenting); however, this
was not statistically significant (P = .059), which may be
explained by the small sampling size. The freedom from
≥50% recurrent restenosis rates at 6 months and 1, 2, and
3 years were 100%, 100%, 100%, and 100%, respectively,
for reoperation versus 100%, 94%, 65%, and 44%, respec-
tively, for the stented group (P = .0001).
In conclusion, carotid PTA/stenting has a 30-day
stroke rate similar to that of reoperation for carotid resteno-
sis once experience is established. However, PTA/stenting
has a higher incidence of recurrent restenosis than reopera-
tion, which may be associated with cranial nerve injury.
Therefore, PTA/stenting can be an alternative for reopera-
tion, particularly in marginal surgical risk patients. In the
future, carotid protection devices may further reduce the
risk of periprocedural embolic events, and stents coated
with drugs may reduce restenosis; however, at this stage,
the exact role of transcatheter intervention in the manage-
ment of carotid artery restenosis remains to be seen.
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Dr Michael B. Silva (Lubbock, Tex). I would like to congrat-
ulate Dr AbuRahma on an excellent presentation and his group
for the careful examination of their experience in initiating a pro-
gram in carotid angioplasty and stenting. I have a few questions.
With the average time to restenosis in both groups approxi-
mately three and a half years after initial carotid endarterectomy,
the probability is that these stenoses were recurrent atherosclerotic
lesions rather than myointimal hyperplastic lesions. Did you look
at angiographic or duplex characteristics which might better… 
[end of cassette]
… your insights as to the potential for reducing risks to an
appropriate level which would justify more widespread adoption
of these practices by the surgeons in this room.
Thank you very much, Ali, for providing me with the manu-
script well in advance and thank you to the society for the privi-
lege of the floor.
Dr Ali F. AbuRahma. I appreciate your comments. In regards
to recurrent stenosis in these cases, they were as you suggested.
Most of the perioperative strokes occurred in patients with late
recurrent stenosis (>24 months). Actually, 3 out of 4 patients who
had early strokes in the PTA/stenting group were related to late
recurrent stenosis, and 1 out of 2 patients with early stroke in the
reoperation group were also related to recurrent stenosis.
The type of stenting used included two Palmaz stents in our
early experience, followed by 11 Wall stents, and the last 12 cases
were Smart stents.
It is true that the recurrent stenoses in the PTA group were
much higher, but most of these were asymptomatic.
Finally, in regard to the experience of the operator (MB), the
peripheral interventionalist had performed over several thousand
various peripheral vascular interventions, including aortoiliac,
femoropopliteal, renal/subclavian/brachiocephalic. At least 40 of
these were carotid PTA/stenting. He has extensive experience in
peripheral vascular intervention.
Dr Nicos Labropoulos (Maywood, Ill). I just want to make a
general comment. About a year ago, the University of Chicago
asked me to give a talk on recurrent carotid stenosis. To my sur-
prise, I looked at all the literature and I found out that the inci-
dence of events in people who have recurrent carotid stenosis is
very low. If your meta-analysis shows a 4.2% event rate after the
procedure, should we do this operation at all? Your question
might be that recurrent carotid stenosis might lead to occlusion.
Unfortunately, in the prospective fashion, nobody has studied
the natural history of recurrent carotid stenosis. If we look at the
data on atherosclerosis, there is only one paper from Moneta
showing that if you have an atherosclerotic primary lesion, the
occlusion rate is 11% at 3 years. However, there are no such data
for recurrent carotid stenosis. With such a high incidence of
events, it is really questionable if we should do anything about
these patients at all.
Dr AbuRahma. I would like to point out, as I presented ear-
lier, that the indication for the reoperation PTA/stenting was
primarily for symptomatic patients (TIA/stroke), specifically 79%
in the reoperation group and 72% in the PTA/stenting group.
The remaining indications were for ≥80% asymptomatic stenosis.
Dr Alan Lumsden (Atlanta, Ga). There is clearly a huge dif-
ference between your early and your late experience. Part of that
is where you draw the line and say this is the definition of early
and this is the definition of late. If you look at your last major
event and say everything after that which is incident-free is late,
it is going to be pretty impressive data when you look at it. What
was the duration of your early experience versus the later experi-
ence? 
Dr AbuRahma. That is a good point. The time frame for the
PTA/stenting were: the first 12 cases were done over the first 26
months and the remaining 13 were done over the remaining 18
or 19 months. 
Dr John Ricotta (Stony Brook, NY). Ali, let me just ask you
one question. There had been some concern about manipulation
and recurrent stenosis in patients who have patches in terms of
higher event rate. Do you know how many of them had patches
and how many did not?
Dr AbuRahma. That is a good point. Actually, all of the
stenting were primary closures except two patients with patches,
so it would be difficult to tell you whether patching had anything
to do with it or not.
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